These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 12563675)

  • 1. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.
    Chakravarty EF; Sanchez-Yamamoto D; Bush TM
    J Rheumatol; 2003 Feb; 30(2):241-6. PubMed ID: 12563675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy.
    Erkan D; Yazici Y; Harrison MJ; Paget SA
    Arthritis Rheum; 2002 Jun; 47(3):285-90. PubMed ID: 12115159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE; Hong P; Koehler BE
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease.
    Østensen M; von Esebeck M; Villiger PM
    J Rheumatol; 2007 Jun; 34(6):1266-9. PubMed ID: 17516615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey.
    Saraux A; Devauchelle-Pensec V; Engerran L; Flipo RM
    J Rheumatol; 2006 Jul; 33(7):1258-65. PubMed ID: 16783865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional DMARD options for patients with a suboptimal response to methotrexate.
    O'Dell J
    J Rheumatol Suppl; 2001 Jun; 62():21-6. PubMed ID: 11409154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
    van Riel PL; Freundlich B; MacPeek D; Pedersen R; Foehl JR; Singh A;
    Ann Rheum Dis; 2008 Aug; 67(8):1104-10. PubMed ID: 17666447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.
    Maetzel A; Bombardier C; Strand V; Tugwell P; Wells G
    J Rheumatol; 1998 Dec; 25(12):2331-8. PubMed ID: 9858426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.
    Zink A; Listing J; Ziemer S; Zeidler H;
    J Rheumatol; 2001 Oct; 28(10):2201-8. PubMed ID: 11669156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A; Buchbinder R; Mylvaganam A; Hall S; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing length of time taking methotrexate in rheumatoid arthritis.
    Ortendahl M; Schettler JD; Fries JF
    J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pregnant and non-pregnant rheumatic patients: a survey among Dutch rheumatologists.
    Vroom F; van de Laar MA; van Roon EN; Brouwers JR; de Jong-van den Berg LT
    J Clin Pharm Ther; 2008 Feb; 33(1):39-44. PubMed ID: 18211615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I; Carmona L; Balsa A; Sanmarti R; Belmonte MA; Tena X;
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
    Bao C; Chen S; Gu Y; Lao Z; Ni L; Yu Q; Xu J; Li X; Liu J; Sun L; He P; Ma J; Xu S; Ding C
    Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.